

CURRICULUM VITAE
IVAN LANDIRES MD, MSC, PhD

DATOS GENERALES:

Estado civil: Casado

Fecha de nacimiento: 19 de enero de 1971

Cédula: PE-8-2199

Nacionalidad: Panameña

<https://orcid.org/0000-0001-6323-1170>

<https://scholar.google.com/citations?user=IOXf904AAAAJ&hl=en>

<https://pubmed.ncbi.nlm.nih.gov/?term=Landires+i.&sort=date>

<https://www.institutodecienciasmedicas.org>

Índice h: 31

Correos electrónicos:

ilandires@institutodecienciasmedicas.org

ivanlandires@yahoo.es

Educación:

2001 Médico y cirujano.

Universidad del Cauca, Colombia.

1999 Internship. Immunogenetics Unit, Dana Farber Cancer Institute .
Harvard Medical School, Boston, USA.

2002 Internship. Molecular Biology and Evolution Laboratory.
Smithsonian Tropical Research Institute. Panamá.

2003 - 2004. Médico Interno Hospital Santo Tomas, Panama.

2004-2005. Médico Interno Hospital Cecilio Castellero, Herrera, Panama.

2006-2007. Maestría. Universidad Paris Diderot – Paris 7. France.

Genómica

2007-2008. Maestría en Genética. **Especialidad en Genética Humana**
Universidad Paris 11. Francia.

2008-2011. PhD. Doctorado en Institut Pasteur y Universidad de Paris 7

2013-2016. Especialidad maestría en ciencias clínicas en Pediatría. Universidad de Panamá

DISTINCIONES:

1. Ganador Primer Lugar Concurso Nacional de Oratoria Caja de Ahorros 1985, representando al Colegio José Daniel Crespo y a la provincia de Herrera
2. Miembro fundador Instituto de Ciencias Médicas, Azuero, Panamá
3. Investigador del Sistema Nacional de Investigación de la Senacyt desde 2012
4. Comisionado Mesa de Salud del Pacto del Bicentenario 2021
5. Experto del Comité de Enfermedades Genéticas y Raras de la Organización Mundial de la Salud, OMS.
6. Investigador Distinguido SNI, Sistema Nacional de Investigación de Panamá, SENACYT

PUBLICACIONES MEDICAS Y CIENTIFICAS INDEXADAS EN Web of Science, Journal Citations Reports y/o Scopus

1. Núñez-Samudio V, Arcos-Burgos M, **Landires I**. Rare diseases: democratising genetic testing in LMICs. *Lancet (London, England)*. 2023;401(10385):1339-1340. doi:10.1016/S0140-6736(23)00343-4
2. Molina MA, Melchers WJG, Núñez-Samudio V, **Landires I**. The emerging role of *Lactobacillus acidophilus* in the cervicovaginal microenvironment. *Lancet Microbe*. 2024;5(1):e6-e7. doi:10.1016/S2666-5247(23)00315-4
3. Núñez-Samudio V, Herrera M, Herrera G, Pimentel-Peralta G, **Landires I**. The Molecular Genetic Epidemiology and Antimicrobial Resistance of *Neisseria gonorrhoeae* Strains Obtained from Clinical Isolates in Central Panama. *Microorganisms*. 2023;11(10):2572. Published 2023 Oct 16. doi:10.3390/microorganisms11102572
4. **Landires I**, Castellero I, Ramos I, Núñez-Samudio V. Mining threatens health of Panama's environment. *SCIENCE*. 2023;382(6674):1007-1008. doi:10.1126/science.adm7959
5. GBD 2021 Nervous System Disorders Collaborators. Global, regional, and national burden of disorders affecting the nervous system, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021 [published correction appears in *Lancet Neurol*. 2024 Mar 18;:]. *Lancet Neurol*. 2024;23(4):344-381. doi:10.1016/S1474-4422(24)00038-3

6. GBD 2021 Fertility and Forecasting Collaborators. Global fertility in 204 countries and territories, 1950-2021, with forecasts to 2100: a comprehensive demographic analysis for the Global Burden of Disease Study 2021. *Lancet*. Published online March 19, 2024. doi:10.1016/S0140-6736(24)00550-6

7. GBD 2021 Tuberculosis Collaborators. Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 2021. *Lancet Infect Dis*. Published online March 19, 2024. doi:10.1016/S1473-3099(24)00007-0

8. Pesudovs K, Lansingh VC, Kempen JH, et al. Global estimates on the number of people blind or visually impaired by cataract: a meta-analysis from 2000 to 2020. *Eye (Lond)*. Published online March 9, 2024. doi:10.1038/s41433-024-02961-1

9. Mensah GA, Fuster V, Murray CJL, Roth GA; Global Burden of Cardiovascular Diseases and Risks Collaborators. Global Burden of Cardiovascular Diseases and Risks, 1990-2022. *J Am Coll Cardiol*. 2023;82(25):2350-2473. doi:10.1016/j.jacc.2023.11.007

10. GBD 2021 Other Musculoskeletal Disorders Collaborators. Global, regional, and national burden of other musculoskeletal disorders, 1990-2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. *Lancet Rheumatol*. 2023;5(11):e670-e682. Published 2023 Oct 23. doi:10.1016/S2665-9913(23)00232-1

11. GBD 2021 Carbon Monoxide Poisoning Collaborators. Global, regional, and national mortality due to unintentional carbon monoxide poisoning, 2000-2021: results from the Global Burden of Disease Study 2021. *Lancet Public Health*. 2023;8(11):e839-e849. doi:10.1016/S2468-2667(23)00185-8

12. GBD 2021 Anaemia Collaborators. Prevalence, years lived with disability, and trends in anaemia burden by severity and cause, 1990-2021: findings from the Global Burden of Disease Study 2021 [published correction appears in *Lancet Haematol*. 2023 Oct;10(10):e796] [published correction appears in *Lancet Haematol*. 2024 Jan;11(1):e10]. *Lancet Haematol*. 2023;10(9):e713-e734. doi:10.1016/S2352-3026(23)00160-6

13. Courville, K. J., Bustamante, N. E., Nuñez-Samudio, V., Pecchio, M., **Landires, I.**, Viggiano, C., Durán, H., Novoa, N., Alvarado, E., Vargas, F., Salado, D., Manzanares, J., Houghton, K., Cuero, C., Niedda, M., & Valdés, R. (2023). Vaccination and mortality from COVID-19: a comparative study between hemodialysis, peritoneal dialysis, and non-dialysis adult population in Panama. *International urology and nephrology*, 55(8), 2091–2098. <https://doi.org/10.1007/s11255-023-03529-w>

14. The Global, Regional, and National Burden of Adult Lip, Oral, and Pharyngeal Cancer in 204 Countries and Territories: A Systematic Analysis for the Global Burden of Disease Study 2019 [published online ahead of print, 2023 Sep 7]. *JAMA Oncol*. 2023;e232960. doi:10.1001/jamaoncol.2023.2960

15. Global, regional, and national burden of meningitis and its aetiologies, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet Neurol.* 2023;22(8):685-711. doi:10.1016/S1474-4422(23)00195-3
16. Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000-2021: a systematic analysis from the Global Burden of Disease Study 2021. *The Lancet. Haematology*, 10(8), e585–e599. [https://doi.org/10.1016/S2352-3026\(23\)00118-7](https://doi.org/10.1016/S2352-3026(23)00118-7)
17. Núñez-Samudio V, Pimentel-Peralta G, De La Cruz A, **Landires I.** Genetic Diversity and New Sequence Types of *Escherichia coli* Coharboring β -Lactamases and PMQR Genes Isolated from Domestic Dogs in Central Panama. *Genes.* 2023; 14(1):73. <https://doi.org/10.3390/genes14010073>
18. Núñez-Samudio V, Pimentel-Peralta G, Herrera M, Pecchio M, Quintero J, **Landires I.** Molecular Genetic Epidemiology of an Emerging Antimicrobial-Resistant *Klebsiella pneumoniae* Clone (ST307) Obtained from Clinical Isolates in Central Panama. *Antibiotics (Basel).* 2022;11(12):1817. Published 2022 Dec 14. doi:10.3390/antibiotics11121817
19. GBD 2019 Antimicrobial Resistance Collaborators. Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet.* 2023;400(10369):2221-2248. doi:10.1016/S0140-6736(22)02185-7
20. Haeuser E, Serfes AL, Cork MA, et al. Mapping age- and sex-specific HIV prevalence in adults in sub-Saharan Africa, 2000-2018. *BMC Med.* 2022;20(1):488. Published 2022 Dec 19. doi:10.1186/s12916-022-02639-z
21. Reiner RC Jr; LBD Triple Burden Collaborators, Hay SI. The overlapping burden of the three leading causes of disability and death in sub-Saharan African children. *Nat Commun.* 2022;13(1):7457. Published 2022 Dec 6. doi:10.1038/s41467-022-34240-6
22. Dembélé, R., Kambou, M., Traoré, O., Aimé, W., Kaboré, D., Ouédraogo-Kangambega, M., Soulama, I., Arcos Holzinger, M., **Landires, I.**, Kabré, E., Sababenedyo Traoré, A., & Barro, N. (2022). Physicochemical Characteristics and Vitamin A Fortification Levels of Refined Edible Oils Available in the Markets of Ouagadougou, Burkina Faso. *Food*

23. GBD 2019 Benign Prostatic Hyperplasia Collaborators. The global, regional, and national burden of benign prostatic hyperplasia in 204 countries and territories from 2000 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet Healthy Longev.* 2022;3(11):e754-e776. doi:10.1016/S2666-7568(22)00213-6
24. GBD 2019 LRI Collaborators. Age-sex differences in the global burden of lower respiratory infections and risk factors, 1990-2019: results from the Global Burden of Disease Study 2019. *Lancet Infect Dis.* 2022;22(11):1626-1647. doi:10.1016/S1473-3099(22)00510-2
25. GBD 2019 Snakebite Envenomation Collaborators. Global mortality of snakebite envenoming between 1990 and 2019. *Nat Commun.* 2022;13(1):6160. Published 2022 Oct 25. doi:10.1038/s41467-022-33627-9
26. GBD 2019 Diabetes in the Americas Collaborators. Burden of diabetes and hyperglycaemia in adults in the Americas, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet Diabetes Endocrinol.* 2022;10(9):655-667. doi:10.1016/S2213-8587(22)00186-3
27. GBD 2019 Hepatitis B Collaborators. Global, regional, and national burden of hepatitis B, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet Gastroenterol Hepatol.* 2022;7(9):796-829. doi:10.1016/S2468-1253(22)00124-8
28. GBD 2019 Cancer Risk Factors Collaborators. The global burden of cancer attributable to risk factors, 2010-19: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet.* 2022;400(10352):563-591. doi:10.1016/S0140-6736(22)01438-6
29. Courville K, Bustamante N, Hurtado B,and **Landires I.** Chronic kidney disease of nontraditional causes in central Panama. *BMC Nephrol.* 2022;23(1):275. Published 2022 Aug 5. doi:10.1186/s12882-022-02907-3
30. GBD 2019 Adolescent Transport and Unintentional Injuries Collaborators. Adolescent transport and unintentional injuries: a systematic analysis using the Global Burden of Disease Study 2019 [published correction appears in *Lancet Public Health.* 2022 Dec;7(12):e992]. *Lancet Public Health.* 2022;7(8):e657-e669. doi:10.1016/S2468-2667(22)00134-7
31. Courville K, Bernal W, Quiel D, Pecchio M, Bustamante N, **Landires I.** Diagnostic evaluation and assessment of anemia in a patient with chronic kidney disease and gastrointestinal angioectasias undergoing hemodialysis. *Clin Case Rep.* 2022;10(7):e6027. Published 2022 Jul 11. doi:10.1002/ccr3.6027

32. Aguillon D, Vasquez D, Madrigal L, et al. Ataxia with Ocular Apraxia Type 1 (AOA1) (APTX, W279* Mutation): Neurological, Neuropsychological, and Molecular Outlining of a Heterogenous Phenotype in Four Colombian Siblings [published correction appears in *Mol Neurobiol*. 2022 May 19;:]. *Mol Neurobiol*. 2022;59(6):3845-3858. doi:10.1007/s12035-022-02821-7
33. GBD 2019 Colorectal Cancer Collaborators. Global, regional, and national burden of colorectal cancer and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet Gastroenterol Hepatol*. 2022;7(7):627-647. doi:10.1016/S2468-1253(22)00044-9
34. GBD 2019 Ageing Collaborators. Global, regional, and national burden of diseases and injuries for adults 70 years and older: systematic analysis for the Global Burden of Disease 2019 Study. *BMJ*. 2022;376:e068208. Published 2022 Mar 10. doi:10.1136/bmj-2021-068208
35. GBD 2019 Adolescent Young Adult Cancer Collaborators (2022). The global burden of adolescent and young adult cancer in 2019: a systematic analysis for the Global Burden of Disease Study 2019. *The Lancet. Oncology*, 23(1), 27–52. [https://doi.org/10.1016/S1470-2045\(21\)00581-7](https://doi.org/10.1016/S1470-2045(21)00581-7)
36. Global Burden of Disease 2019 Cancer Collaboration, Kocarnik, J. M., Compton, K., Dean, F. E., Fu, W., Gaw, B. L., Harvey, J. D., Henrikson, H. J., Lu, D., Pennini, A., Xu, R., Ababneh, E., Abbasi-Kangevari, M., Abbastabar, H., Abd-Elsalam, S. M., Abdoli, A., Abedi, A., Abidi, H., Abolhassani, H., Adedeji, I. A., ... Force, L. M. (2021). Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019: A Systematic Analysis for the Global Burden of Disease Study 2019. *JAMA oncology*, e216987.
37. Fernández-Marín, H., Bruner-Montero, G., Portugal-Loayza, A., Miranda, V., Villarreal Dominguez, A. E., Ortega-Barría, E., Núñez-Samudio, V., **Landires, I.**, Mejía, L. C., López-Vergès, S., Wcislo, W. T., & Kosagisharaf, J. R. (2021). Dynamics of Mask Use as a Prevention Strategy against SARS-CoV-2 in Panama. *International journal of environmental research and public health*, 18(24), 12982.
38. GBD 2019 Tuberculosis Collaborators (2021). Global, regional, and national sex differences in the global burden of tuberculosis by HIV status, 1990-2019: results from the Global Burden of Disease Study 2019. *The Lancet. Infectious diseases*, S1473-3099(21)00449-7.
39. Vega, S., Acosta, F., **Landires, I.**, Morán, M., Gonzalez, J., Pimentel-Peralta, G., Núñez-Samudio, V., & Goodridge, A. (2021). Phenotypic and genotypic characteristics of carbapenemase- and extended spectrum β -lactamase-producing *Klebsiella pneumoniae ozaenae* clinical isolates within a hospital in Panama City. *Therapeutic advances in infectious disease*, 8, 20499361211054918.
40. GBD 2019 Adolescent Mortality Collaborators (2021). Global, regional, and national mortality among young people aged 10-24 years, 1950-2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet (London, England)*, 398(10311),

1593–1618.

41. GBD 2019 Adolescent Young Adult Cancer Collaborators (2021). The global burden of adolescent and young adult cancer in 2019: a systematic analysis for the Global Burden of Disease Study 2019. *The Lancet. Oncology*, S1470-2045(21)00581-7. Advance online publication.
42. Safiri, S., Kolahi, A. A., Naghavi, M., & Global Burden of Disease Bladder Cancer Collaborators (2021). Global, regional and national burden of bladder cancer and its attributable risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease study 2019. *BMJ global health*, 6(11), e004128.
43. GBD 2019 HIV Collaborators (2021). Global, regional, and national sex-specific burden and control of the HIV epidemic, 1990-2019, for 204 countries and territories: the Global Burden of Diseases Study 2019. *The lancet. HIV*, 8(10), e633–e651.
44. Kinyoki D, Osgood-Zimmerman AE, Bhattacharjee NV; Local Burden of Disease Anaemia Collaborators, Kassebaum NJ, Hay SI. Anemia prevalence in women of reproductive age in low- and middle-income countries between 2000 and 2018. *Nat Med*. 2021;27(10):1761-1782. doi:10.1038/s41591-021-01498-0
45. Núñez-Samudio V, Pecchio M, Pimentel-Peralta G, Quintero Y, Herrera M, **Landires I**. Molecular Epidemiology of *Escherichia coli* Clinical Isolates from Central Panama. *Antibiotics (Basel)*. 2021;10(8):899. Published 2021 Jul 23. doi:10.3390/antibiotics10080899.
46. GBD 2019 Under-5 Mortality Collaborators. Global, regional, and national progress towards Sustainable Development Goal 3.2 for neonatal and child health: all-cause and cause-specific mortality findings from the Global Burden of Disease Study 2019. *Lancet*. 2021;398(10303):870-905. doi:10.1016/S0140-6736(21)01207-1
47. GBD 2019 Respiratory Tract Cancers Collaborators. Global, regional, and national burden of respiratory tract cancers and associated risk factors from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet Respir Med*. 2021;9(9):1030-1049. doi:10.1016/S2213-2600(21)00164-8
48. Núñez-Samudio V, Meza M, **Landires I**. Dengue and hantavirus coinfection with good outcomes: a clinical case from Panama. *BMJ Case Rep*. 2021;14(5):e235779. Published 2021 May 19. doi:10.1136/bcr-2020-235779
49. GBD 2019 Dementia Collaborators. Use of multidimensional item response theory methods for dementia prevalence prediction: an example using the Health and Retirement Survey and the Aging, Demographics, and Memory Study. *BMC Med Inform Decis Mak*. 2021;21(1):241. Published 2021 Aug 11. doi:10.1186/s12911-021-01590-y
50. Courville K, Núñez-Samudio V, **Landires I**. Alport syndrome: update in pathophysiology, genetics, diagnosis, and treatment. *Rev Nefrol Dial Traspl*. [Internet]. 2021Mar.25 [cited 2021Sep.19];41(1):62-1. Available from: <https://www.revistarenal.org.ar/index.php/rndt/article/view/619>

51. GBD 2020, Release 1, Vaccine Coverage Collaborators. Measuring routine childhood vaccination coverage in 204 countries and territories, 1980-2019: a systematic analysis for the Global Burden of Disease Study 2020, Release 1. *Lancet*. 2021;398(10299):503-521. doi:10.1016/S0140-6736(21)00984-3
52. Local Burden of Disease HIV Collaborators. Subnational mapping of HIV incidence and mortality among individuals aged 15-49 years in sub-Saharan Africa, 2000-18: a modelling study. *Lancet HIV*. 2021;8(6):e363-e375. doi:10.1016/S2352-3018(21)00051-5
53. Bhattacharjee NV, Schaeffer LE, Hay SI; Local Burden of Disease Exclusive Breastfeeding Collaborators. Mapping inequalities in exclusive breastfeeding in low- and middle-income countries, 2000-2018. *Nat Hum Behav*. 2021;5(8):1027-1045. doi:10.1038/s41562-021-01108-6
54. Núñez-Samudio V, **Landires I**. Epidemiology of viral respiratory infections in a pediatric reference hospital in Central Panama. *BMC Infect Dis*. 2021;21(1):43. Published 2021 Jan 9. doi:10.1186/s12879-020-05720-1
55. GBD 2019 Chewing Tobacco Collaborators. Spatial, temporal, and demographic patterns in prevalence of chewing tobacco use in 204 countries and territories, 1990-2019: a systematic analysis from the Global Burden of Disease Study 2019 [published correction appears in *Lancet Public Health*. 2021 Jul;6(7):e449]. *Lancet Public Health*. 2021;6(7):e482-e499. doi:10.1016/S2468-2667(21)00065-7
56. GBD 2019 Tobacco Collaborators. Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990-2019: a systematic analysis from the Global Burden of Disease Study 2019 [published correction appears in *Lancet*. 2021 Jun 19;397(10292):2336]. *Lancet*. 2021;397(10292):2337-2360. doi:10.1016/S0140-6736(21)01169-7
57. The Burden of Dementia due to Down Syndrome, Parkinson's Disease, Stroke, and Traumatic Brain Injury: A Systematic Analysis for the Global Burden of Disease Study 2019. *Neuroepidemiology* 2021;55:286-296. doi: 10.1159/000515393
58. GBD 2019 Hearing Loss Collaborators. Hearing loss prevalence and years lived with disability, 1990-2019: findings from the Global Burden of Disease Study 2019. *Lancet*. 2021;397(10278):996-1009. doi:10.1016/S0140-6736(21)00516-X
59. GBD 2019 Blindness and Vision Impairment Collaborators; Vision Loss Expert Group of the Global Burden of Disease Study. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study [published correction appears in *Lancet Glob Health*. 2021 Apr;9(4):e408]. *Lancet Glob Health*. 2021;9(2):e144-e160. doi:10.1016/S2214-109X(20)30489-7
60. Local Burden of Disease HIV Collaborators. Mapping subnational HIV mortality in six Latin American countries with incomplete vital registration systems. *BMC Med* **19**, 4 (2021). <https://doi.org/10.1186/s12916-020-01876-4>

61. Núñez-Samudio V, Mayorga-Marín F, López Castillo H, **Landires I**. Epidemiological Characteristics of Road Traffic Injuries Involving Children in Three Central American Countries, 2012-2015. *Int J Environ Res Public Health*. 2020;18(1):37. Published 2020 Dec 23. doi:10.3390/ijerph18010037
62. GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet*. 2020;396(10258):1223-1249. doi:10.1016/S0140-6736(20)30752-2
63. GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019 [published correction appears in *Lancet*. 2020 Nov 14;396(10262):1562]. *Lancet*. 2020;396(10258):1204-1222. doi:10.1016/S0140-6736(20)30925-9
64. GBD 2019 Viewpoint Collaborators. Five insights from the Global Burden of Disease Study 2019. *Lancet*. 2020;396(10258):1135-1159. doi:10.1016/S0140-6736(20)31404-5
65. Núñez-Samudio V, Jiménez-Domínguez A, López Castillo H, **Landires I**. Epidemiologic Characteristics of Suicide in Panama, 2007-2016. *Medicina (Kaunas)*. 2020;56(9):442. Published 2020 Aug 31. doi:10.3390/medicina56090442
66. GBD 2019 Universal Health Coverage Collaborators. Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet*. 2020;396(10258):1250-1284. doi:10.1016/S0140-6736(20)30750-9
67. GBD 2019 Collaborators. Global mortality from dementia: Application of a new method and results from the Global Burden of Disease Study 2019. *Alzheimer's Dement*. 2021; 7:e12200. <https://doi.org/10.1002/trc2.12200>
68. Núñez-Samudio V, **Landires I**. Public policies based on scientific evidence: child road safety. Políticas públicas basadas en evidencia científica: el caso de la seguridad vial infantil. *Arch Argent Pediatr*. 2020;118(3):e252-e257. doi:10.5546/aap.2020.eng.e252
69. **Landires I**, Núñez-Samudio V, Fernandez J, et al. Calpainopathy: Description of a Novel Mutation and Clinical Presentation with Early Severe Contractures. *Genes (Basel)*. 2020;11(2):129. Published 2020 Jan 25. doi:10.3390/genes11020129
70. **Landires I**, Nuñez-Samudio V, Apraez-Ippolito G, Castro G. Planetary health: a new sociopolitical framework is urgently needed. *Lancet*. 2018;391(10126):1158. doi:10.1016/S0140-6736(18)30685-8
71. **Landires I**, Núñez-Samudio V. Epigenetics, memory, and inheritance. *Neurologia (Engl Ed)*. 2019;34(2):138-139. doi:10.1016/j.nrl.2017.03.002
72. Nuñez-Samudio V, Jaramillo-Morales J, **Landires I**. Prevalence and characteristics of child victims in motor vehicle collisions in Panama. *Traffic Inj Prev*. 2016;17(4):391-393. doi:10.1080/15389588.2015.1092524

73. Núñez-Samudio V, Montenegro E, **Landires I**. Combatting dengue fever with the help of the student population: a community impact strategy. *Aten Primaria*. 2013;45(7):393-394. doi:10.1016/j.aprim.2013.01.004
74. Bugault F, Benati D, Mouthon L, **Landires I**, et al. Altered responses to homeostatic cytokines in patients with idiopathic CD4 lymphocytopenia. *PLoS One*. 2013;8(1):e55570. doi:10.1371/journal.pone.0055570
75. **Landires I**. The post-Darwinist concept of species: a place for Lamarck?. *Lancet*. 2010;375(9717):806. doi:10.1016/S0140-6736(10)60346-7
76. **Landires I**, Bugault F, Lambotte O, et al. HIV infection perturbs interleukin-7 signaling at the step of STAT5 nuclear relocalization. *AIDS*. 2011;25(15):1843-1853. doi:10.1097/QAD.0b013e32834a3678
77. **Landires I**, Núñez-Samudio V, Thèze J. Short communication: nuclear JAK3 and its involvement in CD4 activation in HIV-infected patients. *AIDS Res Hum Retroviruses*. 2013;29(5):784-787. doi:10.1089/aid.2012.0249
78. Juffroy O, Bugault F, Lambotte O, **Landires I**, et al. Dual mechanism of impairment of interleukin-7 (IL-7) responses in human immunodeficiency virus infection: decreased IL-7 binding and abnormal activation of the JAK/STAT5 pathway. *J Virol*. 2010;84(1):96-108. doi:10.1128/JVI.01475-09
79. Núñez-Samudio V, **Landires I**. Ekiri syndrome complicating shigellosis. *Enferm Infecc Microbiol Clin*. 2007;25(7):492-493. doi:10.1157/13108716
80. **Landires I**, Pascale JM, Motta J. The position of the mutation within the LMNA gene determines the type and extent of tissue involvement in laminopathies. *Clin Genet*. 2007;71(6):592-596. doi:10.1111/j.1399-0004.2007.00772.x
81. **Landires I**. Nuevas soluciones diagnosticas para descartar meningitis tuberculosa [New diagnostic solutions to rule out tuberculous meningitis]. *Rev Neurol*. 2009;48(3):167.
82. **Landires I**, Núñez-Samudio V, Landires E. Development of extrapulmonary tuberculosis. *Arch Bronconeumol*. 2007;43(2):129. doi:10.1016/s1579-2129(07)60034-2
83. **Landires I**, Núñez-Samudio V. Genetics and metabolic syndrome: a further opportunity for conducting integrated health interventions. *Aten Primaria*. 2007;39(1):52. doi:10.1016/s0212-6567(07)70837-5
84. Núñez-Samudio V, **Landires I**. Children against dengue. *An Pediatr (Barc)*. 2007;66(1):89. doi:10.1016/s1695-4033(07)70302-8
85. **Landires I**, Núñez-Samudio V, Pascale JM. Adjunctive therapy in tuberculous meningitis and human immunodeficiency virus coinfection. *Enferm Infecc Microbiol Clin*. 2006;24(8):538. doi:10.1157/13092478
86. Baena A, Leung JY, Sullivan AD, **Landires I**, et al. TNF-alpha promoter single nucleotide polymorphisms are markers of human ancestry. *Genes Immun*.

2002;3(8):482-487. doi:10.1038/sj.gene.6363898